Resistant to HIV stop patients in anti-drug therapies

In one study, an anti-HIV drug has increased the movement of viruses with modern HIV infections resistant to drugs and has reduced immune cells. The researchers said that drug use is a passionate strategy for patients who use existing anti-HIV drugs. For some people with HIV, current drug therapy cannot prevent viruses, due to drug resistance and malnutrition.

While many anti-HIV drugs are being targeted effectively, while in the decade, there was no new anti-HIV therapy to combat this disease. In 2018, the FDA approved a drug, ibalizumab, that targeted basic receptors for the entry of HIV into immune cells known as IELTS cells. This new block of action prevents HIV from entering the target cells.

Chinese genetic claims claim that, after winning the HIV virus for human rights, the winning girls in China were born after the change in their genes. During this decade, the development of the Jane Modification Tool has successfully changed science fiction things to potentially dry human genes. Chinese researchers reported on the first successful amendment of human genocide. Thoughtful people continue to advocate against experience in this area unless the technology is more mature and the designer of humanity solves moral problems with children, a Chinese scientist can already monitor the research that Modifications have created two girls with genomes Prevent prevention or prevent HIV infection, which is unusual despite scientific achievements in understanding the interaction between biochemical viruses, individuals and communities of the effective immune response.

It is observed that some people are resistant to HIV infection or the result is research of hosted to identify the biological or behavioral characteristics of these people. These figures can be considered key to the development of appropriate strategies to reduce the effective response of those who are immune. In this article, we study genetic mechanisms that include genetic immune responses for chemokines and their reactions, cytokines, HIV infections, local variables of immune response behavior, coinfection and mechanisms associated with immune-based mechanisms. It is included with We use these observations as a platform for future research to better understand the natural resistance of HIV infection through mathematical modeling of Kohat's studies, population genotype typography, virus interaction and behavior analysis.

Other investigations,
The medication was published in Co-author, MD, New England Journal of Medical, by Yale's Assistant Professor Emo. For some people with HIV, current drug therapy can not prevent viruses, due to drug resistance and malnutrition. While many anti-HIV drugs are being targeted effectively, while in the decade, there was no new anti-HIV therapy to combat this disease. In March 2018, the FDA approved ambulumab, which regulates the basic receptors for HIV entry into immune cells known as CD4T cells. This new block of action prevents HIV from entering the target cells. Multiple sites participated in the study, which includes YE, which includes several HIV-resistant medications. In addition to their failed regimens for patients for a week, a diet of ibalizumab, which has been prevented injection. After this period, they obtained the perfume mixed with optimized treatment regimens for six months.

The research team discovered that after a week with Ibalizumab, the study of 40 40 patients (83%) decreased the burden of the virus, which shows the amount of HIV detected in the blood. After 25 weeks, almost half of the patients saw the vertical load viewing reservoir below the revealed surface. The researchers also increased CD4T cells, which is a hallmark for immune power. The researchers said that an individual experienced an incredible incident, which was related to ibalizumab and was the result of studying. to see the pressure of the viruses, highly resistant HIV patients, represents a new mechanism of action."It is also indirectly transmitted every two weeks and stays longer compared to existing anti-HIV drugs, which are taken every day from the mouth.

Since the first monochloro antibiotics are approved to treat HIV, ibalizumab is a promising option for those who have tried many other medications. "It should be considered for patients who have a lot of resistance to medications, who have seen this study studying the influence," he said. Due to its novel mechanism, ibalizumab will not interact with other drugs negatively. 

"I hope to interact with the community so that said treatment is carried out in accordance with the current treatment of HIV infection." "We must also take care that cardiovascular patients have been diagnosed with patients with more patients than other medications, which generates a great need for HIV patients resistant to multiple drugs." In this way, patients and providers should be careful with side effects. Negative events.